Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$1.99 -3.9%	$1.83	$1.43 ▼ $4.26	$199.82M	1.62	145,007 shs	150,325 shs
CTMX CytomX Therapeutics	$2.37 -5.2%	$2.06	$0.40 ▼ $3.10	$191.07M	2.05	2.20 million shs	1.99 million shs
IPSC Century Therapeutics	$0.55 -0.9%	$0.56	$0.34 ▼ $3.29	$47.83M	1.78	553,785 shs	361,605 shs
MNPR Monopar Therapeutics	$37.20 +2.6%	$35.99	$1.72 ▼ $54.30	$227.66M	1.01	360,924 shs	49,658 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	0.00%	+2.49%	+0.98%	+29.56%	-42.62%
CTMX CytomX Therapeutics	0.00%	+10.67%	-5.68%	+477.06%	+93.02%
IPSC Century Therapeutics	0.00%	+7.96%	-9.14%	+35.89%	-75.00%
MNPR Monopar Therapeutics	0.00%	+6.76%	-3.34%	+24.16%	+896.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACIU AC Immune	1.9606 of 5 stars	3.5	3.0	0.0	0.6	0.8	0.6
CTMX CytomX Therapeutics	3.7931 of 5 stars	3.5	1.0	4.7	0.0	1.7	1.3
IPSC Century Therapeutics	2.0324 of 5 stars	3.5	3.0	0.0	0.0	1.7	0.6
MNPR Monopar Therapeutics	2.8083 of 5 stars	3.4	5.0	0.0	1.9	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	3.00	Buy	$12.00	503.02% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.33	125.04% Upside
IPSC Century Therapeutics	3.00	Buy	$4.20	663.50% Upside
MNPR Monopar Therapeutics	2.83	Moderate Buy	$60.00	61.29% Upside

Current Analyst Ratings Breakdown

Latest IPSC, CTMX, MNPR, and ACIU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2025	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
6/23/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
5/16/2025	IPSC Century Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
5/1/2025	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $12.00
4/14/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$3.25 ➝ $2.50

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$31.02M	6.44	N/A	N/A	$1.29 per share	1.54
CTMX CytomX Therapeutics	$138.10M	1.38	$0.34 per share	6.91	($0.01) per share	-237.00
IPSC Century Therapeutics	$114.90M	0.41	N/A	N/A	$1.90 per share	0.29
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$9.02 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$57.83M	-$0.58	N/A	N/A	N/A	-177.79%	-44.60%	-22.25%	8/5/2025 (Estimated)
CTMX CytomX Therapeutics	$31.87M	$0.48	4.94	N/A	N/A	28.22%	-553.71%	32.21%	8/14/2025 (Estimated)
IPSC Century Therapeutics	-$126.57M	-$0.29	N/A	N/A	N/A	-19.10%	-10.71%	-5.96%	8/14/2025 (Estimated)
MNPR Monopar Therapeutics	-$15.59M	-$3.48	N/A	N/A	N/A	N/A	-55.39%	-51.53%	8/8/2025 (Estimated)

Latest IPSC, CTMX, MNPR, and ACIU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	IPSC Century Therapeutics	-$0.31	$0.89	+$1.20	$0.89	$45.52 million	$109.16 million
5/13/2025	Q1 2025	MNPR Monopar Therapeutics	-$0.65	-$0.38	+$0.27	-$0.38	N/A	N/A
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
4/30/2025	Q1 2025	ACIU AC Immune	-$0.22	-$0.21	+$0.01	-$0.21	$1.99 million	$1.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	N/A	1.53	1.53
CTMX CytomX Therapeutics	N/A	1.73	1.73
IPSC Century Therapeutics	N/A	11.70	11.70
MNPR Monopar Therapeutics	N/A	36.91	36.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
CTMX CytomX Therapeutics	67.77%
IPSC Century Therapeutics	50.20%
MNPR Monopar Therapeutics	1.83%

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
CTMX CytomX Therapeutics	6.60%
IPSC Century Therapeutics	5.00%
MNPR Monopar Therapeutics	20.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	140	100.41 million	95.79 million	Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
IPSC Century Therapeutics	170	86.16 million	81.85 million	Optionable
MNPR Monopar Therapeutics	10	6.12 million	4.86 million	Not Optionable

IPSC, CTMX, MNPR, and ACIU Headlines

Recent News About These Companies

Monopar Therapeutics (NASDAQ:MNPR) Coverage Initiated by Analysts at Cantor Fitzgerald

July 7 at 8:51 AM | marketbeat.com

Chardan Capital Comments on MNPR FY2025 Earnings

June 29, 2025 | americanbankingnews.com

FY2025 Earnings Forecast for MNPR Issued By Chardan Capital

June 29, 2025 | marketbeat.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of "Moderate Buy" from Brokerages

June 28, 2025 | americanbankingnews.com

What is Chardan Capital's Forecast for MNPR FY2025 Earnings?

June 27, 2025 | marketbeat.com

Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy

June 26, 2025 | finance.yahoo.com

Institutional investors own a significant stake of 29% in Monopar Therapeutics Inc. (NASDAQ:MNPR)

June 23, 2025 | finance.yahoo.com

Chardan Capital Initiates Coverage of Monopar Therapeutics (MNPR) with Buy Recommendation

June 23, 2025 | msn.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of "Moderate Buy" by Brokerages

June 23, 2025 | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from Analysts at Chardan Capital

June 23, 2025 | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Trading 0.4% Higher - Time to Buy?

June 12, 2025 | marketbeat.com

Monopar Therapeutics Inc.: Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

June 11, 2025 | finanznachrichten.de

Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know

June 11, 2025 | zacks.com

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

June 11, 2025 | globenewswire.com

Monopar Therapeutics added to Russell 3000 and 2000 indexes, stock up 15%

June 3, 2025 | msn.com

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

June 3, 2025 | globenewswire.com

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

May 14, 2025 | manilatimes.netM

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

May 13, 2025 | globenewswire.com

Monopar Therapeutics Presents Long-Term Efficacy and Safety Data for ALXN1840 in Wilson Disease at EASL International Liver Congress 2025

May 8, 2025 | nasdaq.com

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

May 7, 2025 | globenewswire.com

Why Monopar Therapeutics Inc. (MNPR) is Surging in 2025

April 30, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC, CTMX, MNPR, and ACIU Company Descriptions

AC Immune NASDAQ:ACIU

$1.99 -0.08 (-3.86%)

As of 04:00 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

CytomX Therapeutics NASDAQ:CTMX

$2.37 -0.13 (-5.20%)

Closing price 04:00 PM Eastern

Extended Trading

$2.42 +0.05 (+2.32%)

As of 06:57 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Century Therapeutics NASDAQ:IPSC

$0.55 -0.01 (-0.90%)

Closing price 04:00 PM Eastern

Extended Trading

$0.58 +0.03 (+6.34%)

As of 07:35 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Monopar Therapeutics NASDAQ:MNPR

$37.20 +0.95 (+2.62%)

Closing price 04:00 PM Eastern

Extended Trading

$36.07 -1.13 (-3.05%)

As of 06:24 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time